Mera

The irony is astonishing. But I celebrate this change. To appreciate the history of this medication and how we got here, one must look back roughly fifteen to twenty years to the major litigation involving gabapentin (then marketed as Neurontin). The manufacturer faced substantial penalties for *illegally promoting the drug for numerous conditions beyond its FDA-approved indications.* Those approved uses are limited primarily to: 1. The management of postherpetic neuralgia in adults 2. Adjunctive therapy for partial-onset seizures in patients with epilepsy. Off-label prescribing still remains permissible when supported by sound clinical judgment, appropriate documentation, and consideration of risks and benefits. However,, gabapentin has surged in use extensively for postoperative pain, acute pain, and long-term chronic non-neuropathic pain—uses for which it was never approved and for which supporting evidence is often limited or mixed. Its unscheduled status may contribute to the perception that it is a “safer” alternative, even when it is not the most appropriate therapy for a given patient and even when it conflicts with a careful, individualized assessment of efficacy and risk. Although gabapentin may have a limited role in selected neuropathic conditions or in efforts to reduce the risk of developing complex regional pain syndrome after certain injuries or procedures, its side-effect profile warrants careful consideration. Observational data, including a 2025 study published in Regional Anesthesia & Pain Medicine, have associated repeated gabapentin prescriptions with elevated risks of dementia and mild cognitive impairment. Patients receiving six or more prescriptions showed a 29% higher risk of dementia and an 85% higher risk of mild cognitive impairment within ten years compared with matched controls; risks were notably higher among adults aged 35–49 (more than double the risk of dementia and more than triple the risk of mild cognitive impairment). Additional concerns include depression, suicidal ideation, significant weight gain, and, in many patients, inadequate pain relief. These risks are unnecessary when more appropriate, carefully selected analgesics—consistent with current evidence and FDA labeling—are available and legally prescribable in every state. There is no clinical justification for denying patients adequate pain relief solely as a risk-management strategy for the prescriber. When this occurs, the focus shifts from treating the patient to managing the clinician’s anxiety or institutional pressures. That is not consistent with the professional responsibilities of a physician. The continued preference for an anticonvulsant in settings where evidence of benefit is weak illustrates the lasting influence of earlier enforcement actions and the current climate of heightened scrutiny. Compounding the difficulty for prescribers is the growing reliance by certain federal agencies on decision-support algorithms that flag “high prescribers” without context. These tools have not been independently validated for clinical validity across specialties, and the personnel interpreting them frequently lack the depth of pharmacological and medical training possessed by physicians and pharmacists. Medication decisions are best made by clinicians who understand individual patient factors, including comorbidities, concurrent medications, and metabolic considerations, working in collaboration with pharmacists. They should not be driven by unvalidated algorithmic thresholds applied without corresponding clinical expertise. In short, optimal pain management requires individualized assessment by trained physicians and supported by pharmacists rather than the substitution of unproven algorithms or risk-averse practices that leave patients undertreated. Prescribers should adhere to evidence-based principles, document their reasoning thoroughly, and prioritize the patient’s needs over external pressures.